Mateon and Oncotelic Complete Their Merger and Create a New Immuno-Oncology Company with a Late-Stage Clinical Asset Against Cancer and a Promising Product Pipeline

    NEXT STORY
    NeuroMetrix Reports Q1 2019 Financial Results
    PREV STORY
    Decision by the Board of Directors to acquire own shares
    Subscribe to PM360
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    Novo Nordisk: Ozempic® superior in lowering blood sugar and weight vs placebo, both in combination with SGLT-2 inhibitors

    author_avatar
    NASDAQ Market News

    Capital Increase in Bavarian Nordic A/S as a Result of Employee Warrant Exercise

    COPENHAGEN, Denmark, May 18, 2017 - Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) announced ...

    author_avatar
    NASDAQ Market News

    Pluristem Provides 28-Day Follow Up for Ventilator-Dependent COVID-19 Patients under Compassionate Use Program in Israel and U.S.

    author_avatar
    NASDAQ Market News